Your browser does not support JavaScript!

Santé humaine biotechnologies domaine d'application

505 entreprises et organismes intervenants dans le domaine 'Santé humaine', classés par activité.

Rejoignez la communauté
Trouvez du matériel
LILLY FRANCE
est cité dans une actualité de Labiotech.eu
Le 18/07/2023
Hope for Alzheimer’s patients after Lilly drug results
Eli Lilly and Company has presented full results from its phase 3 TRAILBLAZER-ALZ 2 study showing that donanemab significantly slowed cognitive and functional decline in people with early symptomatic...
www.labiotech.eu
PFIZER
est cité dans une actualité de Labiotech.eu
Le 13/07/2023
Pfizer kicks $25M into CellCentric 
U.K.-based biotechnology company CellCentric has received a strategic investment from Pfizer including $25m to help finance further development of inobrodib, its first-in-class p300/CBP inhibitor to...
www.labiotech.eu
Une question a été posée - Le 05/07/2023
1 entreprise(s)
SANOFI AVENTIS
est cité dans une actualité de Labiotech.eu
Le 02/06/2023
Sanofi drug reduces disease activity in relapsing MS
New data, being presented in a late-breaking session at the 2023 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, demonstrate that frexalimab, Sanofi’s novel second-generation...
www.labiotech.eu
PFIZER
est cité dans une actualité de Labiotech.eu
Le 08/05/2023
Promising results from phase 3 prostate cancer study
Astellas Pharma Inc. and Pfizer Inc. have announced trial results from a phase 3 study on prostate cancer. The results showed XTANDI (enzalutamide) plus leuprolide significantly reduced the risk of...
www.labiotech.eu
LILLY FRANCE
est cité dans une actualité de Labiotech.eu
Le 04/05/2023
Positive study results: Lilly’s Alzheimer’s drug slows patients’ decline 
Eli Lilly and Company has announced positive results of the TRAILBLAZER-ALZ 2 phase 3 study showing that donanemab significantly slowed cognitive and functional decline in people with early...
www.labiotech.eu
PFIZER
est cité dans une actualité de Labiotech.eu
Le 15/03/2023
Pfizer’s $43B Seagen acquisition doubles early-stage oncology clinical pipeline
Pfizer Inc. is set to acquire Seagen Inc. for $229 in cash per Seagen share for a total enterprise value of $43 billion. Seagen is a global biotechnology company that discovers, develops and...
www.labiotech.eu
SANOFI AVENTIS
est cité dans une actualité de Labiotech.eu
Le 14/03/2023
Sanofi adds diabetes drug through Provention Bio $2.9B acquisition
Sanofi and Provention Bio, Inc., a U.S.-based, publicly traded biopharmaceutical company focused on intercepting and preventing immune-mediated diseases including type 1 diabetes (T1D), have entered...
www.labiotech.eu
MERCK MILLIPORE
est cité dans une actualité de Labiotech.eu
Le 28/12/2022
Merck and Kelun-Biotech collaborating on seven ADC cancer candidates 
Merck (MSD outside of the U.S. and Canada), and Kelun-Biotech (a holding subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd), have entered into an exclusive license and collaboration agreement to...
www.labiotech.eu
MERCK MILLIPORE
est cité dans une actualité de Labiotech.eu
Le 28/12/2022
Mersana Therapeutics and Merck to develop novel ADCs
Mersana Therapeutics, Inc. has announced a research collaboration and commercial license agreement with a subsidiary of Merck KGaA, Darmstadt, Germany to discover novel Immunosynthen antibody drug...
www.labiotech.eu
Charger plus d'actualités